Ignite Creation Date:
2024-05-05 @ 6:32 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00503854
Status:
COMPLETED
Last Update Posted:
2018-10-22
First Post:
2007-07-17
Brief Title:
Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
Fatigue and Symptom Burden in Febrile Neutropenia
Status:
COMPLETED
Status Verified Date:
2018-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial studies how fatigue and symptom burden in low-risk cancer patients undergoing treatment for febrile neutropenia Cancer and numerous cancer treatments are associated with various symptoms including anemia fever and neutropenia which may also be associated with fatigue Treating low-risk cancer patients for febrile neutropenia may reduce levels of fatigue
Detailed Description:
PRIMARY OBJECTIVES I To determine whether fatigue improves as patients are treated for febrile neutropenia Day 1 Day 2 and Day 6
SECONDARY OBJECTIVES I To identify clinical factors associated in cancer patients with low risk for outpatient treatment of febrile neutropenia on either outpatient febrile neutropenia treatment pathway presenting with moderate to severe fatigue
II To describe demographic information in cancer patients with low risk for outpatient treatment of febrile neutropenia and fatigue while enrolled in either of two outpatient febrile neutropenia treatment pathways
OUTLINE
Patients complete a questionnaire on days 1 2 and 6 regarding fatigue sleep disturbance depression and other symptoms
SECONDARY OBJECTIVES I To identify clinical factors associated in cancer patients with low risk for outpatient treatment of febrile neutropenia on either outpatient febrile neutropenia treatment pathway presenting with moderate to severe fatigue
II To describe demographic information in cancer patients with low risk for outpatient treatment of febrile neutropenia and fatigue while enrolled in either of two outpatient febrile neutropenia treatment pathways
OUTLINE
Patients complete a questionnaire on days 1 2 and 6 regarding fatigue sleep disturbance depression and other symptoms
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| P30CA016672 | NIH | M D Anderson Cancer Center | httpsreporternihgovquickSearchP30CA016672 |
| NCI-2018-02184 | REGISTRY | None | None |
| 2005-0936 | OTHER | None | None |